4.67% -0.2056

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스

Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright - Defense World

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor ... - StockTitan

Amplitude, Inc. (NASDAQ:AMPL) Short Interest Up 34.5% in May - Defense World

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 36.0% in May - Defense World

Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Decreases By 34.6% - Defense World

Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Rises By 47.0% - Defense World

Aprea Therapeutics Insiders Lose Out As Stock Sinks To US$4.23 - Simply Wall St

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock - Yahoo Finance

Aprea Therapeutics Advances Cancer Treatment Trial to Higher Dose Level - MyChesCo

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 64.3% in May - Defense World

Aprea advances cancer drug ATRN-119 in clinical trial By Investing.com - Investing.com

Acute Myeloid Leukemia Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies ... - openPR

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year? - Yahoo New Zealand News

Ovarian Cancer Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per - EIN News

Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q2 2024 Earnings of ($0.69) Per Share, Wedbush Forecasts - Defense World

Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q2 2024 Earnings of ($0.69) Per Share, Wedbush Forecasts - Defense World

Wedbush Analysts Lower Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

Aprea Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.58) Per Share, HC Wainwright Forecasts (NASDAQ:APRE) - Defense World

Wedbush Analysts Lower Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

ArriVent BioPharma Bolsters Board with Biopharmaceutical Expert Dr. John Hohneker - MyChesCo

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MSN

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World

Learn to Evaluate (APRE) using the Charts - Stock Traders Daily

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

Aprea Therapeutics' (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World

Aprea Therapeutics' (APRE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update - Investing.com India

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference - Yahoo Finance

Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 - MyChesCo

Mineralys Therapeutics Reports Robust Financial Results for Q1 2024 - MyChesCo

Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions? - Yahoo Lifestyle Australia

Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MyChesCo

Aprea Therapeutics appoints new chief medical officer By Investing.com - Investing.com

Aprea Therapeutics Appoints Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer - citybiz

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aprea Therapeutics appoints new chief medical officer By Investing.com - Investing.com

Where are the Opportunities in (APRE) - Stock Traders Daily

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel ... - Investing.com Canada

FDA Clearance Paves Way for Aprea Therapeutics' Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial - MyChesCo

symbol__ Stock Quote Price and Forecast - CNN

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 - InvestorPlace

Aprea Therapeutics CFO buys $7,362 in company stock By Investing.com - Investing.com UK

Aprea Therapeutics CFO buys $7,362 in company stock By Investing.com - Investing.com

Aprea Therapeutics Secures Funding and Advances Drug Pipeline - TipRanks

Aprea Therapeutics Secures Funding and Advances Drug Pipeline - TipRanks.com - TipRanks

APRE과 유사한 종목